Twenty cows, a Soviet zapper, and a thymus elixir

Picture a Russian dairy farm, a pregnant cow, a syringe and a small electronic box. This scene comes from a published protocol, not an eyewitness account.

The syringe held a cocktail called the "Bioinformation Elixir," injected into the skin at acupuncture points along the animal's body.

The box had an applicator electrode. It went against the cow's sacrum, then against the skin between her anus and her vulva. When she started shifting her hindquarters away, the operator turned the power down until she stopped fidgeting.

This was a repeated regimen, begun before calving and continued during it, not one injection followed by a wait. The researchers recorded how long the births took.

The study appeared in 2010 in the journal of the Kazan State Academy of Veterinary Medicine, and became part of a Doctor of Veterinary Sciences dissertation defended in 2011. It involved twenty cows. Pull on its threads and you end up in a Cold War radio-engineering institute, a Leningrad military medical lab, a 1947 frog-distillation experiment, and a fight between Soviet inventors that is still running on their company websites.

It's a small story. It explains a big one: how Russia came to have a whole ecosystem of "biomodulators," "bioregulators," and "bioinformation" therapies, and why it's so hard to tell what, if anything, in it works.

What was in the syringe?

According to the dissertation account, the Bioinformation Elixir contained four things.

• Thymalin. A polypeptide extract of calf thymus, developed in the 1970s by the Soviet military physicians Vyacheslav Morozov and Vladimir Khavinson at the Kirov Military Medical Academy in Leningrad. It belongs to the Soviet programme of peptide bioregulators. Epitalon came from a different branch of that programme, based on the pineal extract epithalamin, not thymalin.
• Gamavit. A Russian veterinary immunostimulant.
• ASD-2. "Dorogov's antiseptic-stimulator, fraction 2," created in 1947 at the All-Union Institute of Experimental Veterinary Medicine by A.V. Dorogov. The first raw material was frogs. Today it is made by dry distillation of meat-and-bone meal, heating animal tissue until it breaks down into a pungent mix of small molecules. Russian pet shops still sell it.
• Ringer-Locke. Salt water with a few electrolytes.

So: a thymus extract, an immunostimulant, a postwar Soviet distillate and saline, mixed and injected at acupuncture points. Why those points, and why "bioinformation"? The author explains it himself.

"A microdose of the elixir, injected into the acupuncture point that reflects the diseased organ, brings that organ back to normal. This happens through the point-specific bioinformation resonance action of the elixir's composition on the organ." Микродоза эликсира, введенная в акупунктурную точку, отражающую больной орган, приводит этот орган в норму. Происходит это за счет точечного биоинформационного резонансного воздействия состава эликсира на орган.

The paper never defines a measurable "bioinformation resonance" or tests that mechanism. It does show where the idea came from. The method follows G.V. Kazeev, author of the Russian manual Veterinary Acupuncture (2000) and of work on "information therapy of animal diseases through acupuncture points." The claim is that a drug delivers information as well as molecules, and an acupuncture point routes that information to the right organ.

Hold on to the word information. It comes back.

And what was the box?

To understand the DiaDENAS you have to go to Taganrog, a port on the Sea of Azov. In the Soviet era it was home to the Taganrog Radio-Engineering Institute, named after V.D. Kalmykov, who ran the Soviet radio industry, the ministry that built radar and electronics for the military. In the 1970s the institute had a small department of medical electronics. By the early 1980s it had become a special design bureau called OKB "RITM," which means "Rhythm."

The idea the Taganrog engineers were chasing was straightforward and clever. TENS units deliver electrical pulses through the skin; their settings and modes vary. These engineers proposed a particular feedback loop: what if the device listened to the skin between pulses and adjusted its output to what it heard?

The idea is visible in the paperwork. On 4 January 1987 the institute itself filed a Soviet application for an "Electrostimulator," application SU 4171898/14. The inventors were V.G. Zakharevich, A.I. Nechushkin, A.A. Karasev, A.N. Revenko and A.A. Kibirev. The design reads the electrical transient after each pulse. If the tissue responds in a way the inventors associated with pathology, the device cuts the pulse train short. That is the patent's proposed operation, not clinical validation of its diagnostic or therapeutic claims.

A second application, filed in March 1989, became a US patent in 1993. It states the principle plainly.

That's SCENAR, the Self-Controlled Energo-Neuro-Adaptive Regulator: a TENS unit with a feedback loop. It isn't magic, and as engineering it's rather neat.

The DiaDENAS on that cow is SCENAR's grandchild. In the mid-1990s, after the Soviet Union collapsed and its engineers went into business, a group in Moscow and Yekaterinburg built their own version and called it DENAS. The later dissertation account dates Russian registration of "dynamic electroneurostimulation" as a new medical technology to 2005. A family of devices followed: DiaDENS-T, DiaDENS-Kardio, DENAS-Vertebra, and versions for vets.

Wait, what about the cosmonauts?

If you've read about SCENAR in English you've probably met the space story: built for Soviet cosmonauts, to treat illness in orbit without drugs.

The patents cited here do not mention a space programme. Neither do the dissertation excerpts reviewed for this article. That is a limit of the record examined here, not proof that no such connection ever existed.

The space claim appears in a promotional history which says SCENAR was developed for the Russian space programme, then says no device had flown. It attributes that to waterproofing delays and the programme's end during perestroika.

OKB RITM's own history also names the Cosmonaut Training Centre as a customer and speculates that the SCENAR contract's numbered-mailbox customer belonged to the space agency. The contract page it reproduces identifies a mailbox, not that customer's parent organisation. These are leads, not confirmation that SCENAR was commissioned for use in orbit or ever flew.

The paper trail holds two odd details: a publication delay and a military citation. The 1987 application wasn't published until 27 August 1995, more than eight years after filing. A certificate scan supplied by OKB RITM records registration on 11 October 1992 and bears a termination annotation dated 23 April 1993. The company says a Russian patent replaced the Soviet authorship certificate that day. This was a reported conversion, not simply the invention's expiry. Its history also says the document had been marked for official use before publication. We have not independently checked those claims against the patent-office register; the delay alone establishes neither secrecy nor its absence.

The citation is in Exhibit I. When OKB RITM patented a new stimulator in 1997, the prior art it had to beat included two 1994 electrostimulator patents from a Soviet military aviation school in Chelyabinsk. That shows military institutions were building electrostimulators in the same patent class. It does not show SCENAR was a military or space device. It is still the only military link we found in the documents rather than the brochures.

The founders tell different histories

Karasev, Revenko and OKB RITM place the beginning at different moments. A prototype, a clinical trial and a development contract are not the same event, so different dates need not contradict each other. These are also accounts written by people with competing commercial interests.

The engineer, Alexander Karasev, says he built a Russian TENS device in 1973, tested an early model at a Sochi sanatorium in the mid-1970s, and only gave a device to the neurologist Alexander Revenko in 1983–85. He left in 1990, started his own company, and still sells devices under the SCENAR name.

In a reproduced account by the neurologist Alexander Revenko, trials begin in 1978. He says the device was first called "CENAR" and was renamed SCENAR in 1985 on the advice of, among others, the president of the Russian Acupuncture Association. He writes that Karasev "continues to produce many devices under the name SCENAR, for which he has no permission from OKB RITM," and lists the rivals that split off in 1996, including DENAS, which he credits to "A. Ryavkin."

The company, OKB RITM, dates its founding to May 1980. Its reproduced development contract is dated 12 December 1986.

The regulatory dates describe different steps. Revenko's account places the presentation to the health ministry in 1986. A committee minute reproduced by OKB RITM, dated 14 November 1990, recommends the SCENAR-033 for production and use in medical practice. A 2013 dissertation by S.Yu. Ryavkin gives 1991 for ministry approval. The 1990 scan documents a recommendation for one model, not a blanket approval of every later SCENAR or DENAS device. The final authorisation record still needs checking.

Karasev dates his first TENS device to 1973. No pre-1987 Karasev or Revenko medical patent was found in the searches for this article, but that does not disprove an earlier prototype. The 1987 filing cites SU 865300, filed in 1979 and published in 1981, from a different lab: L.I. Kalakutsky, Kuibyshev Aviation Institute.

The promotional histories reviewed here are useful evidence of what each business claims, not an independent history of the device.

The boom

Why did this take off in the 1990s? The general director of OKB RITM from 1998 to 2012, Yakov Grinberg, wrote it down.

A 2003 conference in Bulgaria drew people from 20 countries. The machine produced a literature to match. By the 2000s there were Russian dissertations pairing SCENAR with almost anything: sleeping pills for insomnia in ambulance doctors, calcium-channel blockers for blood-pressure crises, Arthrofoon (an ultra-diluted antibody drug) for peritonitis. Several came out of one department at Rostov State Medical University. The pattern was always the same: a drug plus the box.

Our veterinarian did the farm version. A Soviet peptide plus the box.

So did it work on the cows?

Both groups had ten cows. All twenty were chosen because the author's own forecasting index, published in 2005, predicted a difficult birth.

All control cows received obstetric assistance; one had the placenta removed manually. The ± values are reproduced from the paper, rounded here. The accessible transcription does not make clear which measure of variability they represent.

On its face that is a large difference: the recorded durations were roughly halved. Now look at what the paper doesn't report. It doesn't say the cows were randomly assigned. It doesn't say whoever timed the births was blinded. With ten animals per group and no stated randomisation or blinding, the comparison does not establish that the treatment caused the difference.

There is no group that got the elixir without the box, or the box without the elixir, and no sham device. Even a reliable benefit from the combination would not tell us which component contributed, or how much came from the additional handling.

In the dissertation account, the author reports a low-hazard classification and no irritation or sensitisation in the tests described. We have not inspected the underlying laboratory report. That is not a comprehensive safety assessment for this regimen, including its effects on pregnancy, calves or residues in food. Nor does it establish a benefit. "Bioinformation resonance" restoring "any diseased organ" is not a mechanism this study defines or tests.

What does better evidence say about the box?

Outside cow barns, SCENAR and its relatives have been tested more rigorously. The results are mixed.

The Spanish paper's table gives 23/33 responders with active treatment and 16/33 with sham at one month; its narrative gives 15 sham responders. The authors report p = 0.014. A simple binary comparison of the table's counts does not reproduce that value. This is not a reanalysis of patient-level data or the authors' stratified and follow-up analyses. The discrepancy needs clarification, not a silently substituted p value. See the original paper.

These studies address different devices and conditions. They do not establish a general therapeutic effect, and none tests the cow regimen.

A useful distinction comes from inside the company. In the same 2004 paper, Grinberg, then running the firm that makes SCENAR, defended the treatment's effectiveness while questioning the evidence for its proposed mechanisms.

The information signal. There's that word again.

Why this matters

It's tempting to file this under weird Russian cow science and move on. But the study shows how different kinds of evidence can get bundled together. The feedback loop has a patent. The thymus extract has a history in military medicine. The space story has promotional copy. None of those establishes that the combination helps a cow give birth, or that "bioinformation resonance" explains an observed difference. A device's engineering and a treatment's evidence are separate questions, however neatly the sales story joins them.

The twenty cows didn't ask for any of this. They had their calves, faster, if you believe one small study that never says it was blinded. That, in the end, is the problem.

The record, claim by claim

Timeline

Sources: patents and registries (P), dissertations and journals (T), vendor histories and memoirs (V).